Expression of MCSP and PRAME in conjunctival melanoma

British Journal of Ophthalmology

Volumn 94, Issue 10, 2010, Pages 1322-1327

  Westekemper, Henrike ^a   Karimi, Sara ^a   Süsskind, Daniela ^b   Anastassiou, Gerasimos ^a   Freistühler, Michael ^a   Meller, Daniel ^a   Zeschnigk, Michael ^a   Steuhl, Klaus Peter ^a   Bornfeld, Norbert ^a   Schmid, Kurt Werner ^a   Grabellus, Florian ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA ANTIGEN; PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA; PROTEOCHONDROITIN SULFATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; CONJUNCTIVA TUMOR; CONJUNCTIVAL MELANOMA; CONJUNCTIVAL NEVI; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEVUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE RISK; SKIN METASTASIS;

ANTIGENS, NEOPLASM; CHONDROITIN SULFATE PROTEOGLYCANS; CONJUNCTIVAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEVUS OF OTA; OBSERVER VARIATION; ROC CURVE; SKIN NEOPLASMS;

EID: 77958543711     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.167445     Document Type: Article

References (39)

1. Seregard S, Kock E. Conjunctival malignant melanoma in Sweden 1969-1991. Acta Ophthalmol Scand 1992;70:289-96.
2. Missotten G, Keijser S, Keizer RJWD, et al. Conjunctival melanoma in The Netherlands: a nationwide study. Invest Ophthalmol Vis Sci 2005;46:75-82.
3. Shields J, Shields C, Mashayekhi A, et al. Primary acquired melanosis of the conjunctiva: risks for progression to melanoma in 311 eyes. The 2006 Lorenz E. Zimmerman lecture. Ophthalmology 2008;115:511-19.
4. Paridaens AD, Minassian DC, MacCarty CA, et al. Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol 1994;78:252-9.
5. Anastassiou G, Heiligenhaus A, Bechrakis N, et al. Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J Ophthalmol 2002;86:163-7.
6. Damato B, Coupland S. An audit of conjunctival melanoma treatment in Liverpool. Eye 2009;23:801-9.
7. Keijser I, Missotten G, Bonfrer J, et al. Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions. Br J Ophthalmol 2006;90:213-17.
8. Esmaeli B, Wang X, Youssef A, et al. Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology 2001;108:2101-5.
9. Iwamoto S, Burrows R, Grossniklaus H, et al. Immunophenotype of conjunctival melanomas: comparisons with uveal and cutaneous melanomas. Arch Ophthalmol 2002;120:1625-9.
10. Hurst E, Harbour J, Cornelius L. Ocular melanoma. A review and the relationship to cutaneous melanoma. Arch Dermatol 2003;139:1067-73.
11. Hu D, Yu G, McCormick S, et al. Population-based incidence of conjunctival melanoma in various races and ethnic groups and comparison with other melanomas. Am J Ophthalmol 2008;145:418-23.
12. Folberg R, Mc Lean IW, Zimmermann LE. Malignant melanoma of the conjunctiva. Hum Pathol 1985;16:136-43.
13. Tuomaala S, Eskelin S, Tarkkanen A, et al. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in Whites. Invest Ophthalmol Vis Sci 2002;43:3399-408. (Pubitemid 35334346)
14. Wuestemeyer H, Sauerwein W, Meller D, et al. Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma. Graefes Arch Clin Exp Ophthalmol 2006;244:438-46.
15. Wilson B, Ruberto G, Ferrone S. Immunochemical characterization of a human high molecular weight melanoma associated antigen identified with monoclonal antibodies. Cancer Immunol lmmunother 1983;14:196-201. (Pubitemid 13117135)
16. Bemfield M, Gottc M, Park P, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729-77. (Pubitemid 29449208)
17. Iida J, Pei D, Kang T, et al. Melanome chondroitin sulfate proteoglycan regulates matrix metalloproteinase-dependent human melanoma invasion into type I collagen. J Biol Chem 2001;276:18786-94. (Pubitemid 37411195)
18. Burg M, Grako K, Stallcup W. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J Cell Physiol 1998;177:299-312. (Pubitemid 28452831)
19. Chekenya M, Rooprai H, Davies D, et al. The NG2 chondroitin sulfate proteoglycan: role in malignant progression of human brain tumours. Int J Dev Neurosci 1999;17:421-35. (Pubitemid 29421830)
20. Benassi M, Pazzaglia L, Chiechi A, et al. NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients. J Orthop Res 2009;27:135-40.
21. Iida J, Meijne A, Spiro R, et al. Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and alpha 4 beta 1 integrin. Cancer Res 1995;55:2177-85.
22. Iida J, Wilhelmson K, Ng J, et al. Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A). Biochem J 2007;403:553-63. (Pubitemid 46706984)
23. Ferrone S, Temponi M, Gargiulo D, et al. Selection and utilization of monoclonal antibody defined melanoma associated antigens for immunoscintigraphy in patients with melanoma. In: Srivastava SC, ed. Radiolabeled Monoclonal Antibodies for Imaging and Therapy. New York/London: Plenum Publishing Corp, 1988:55-73.
24. Campoli M, Chang C, Kageshita T, et al. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 2004;24:267-96. (Pubitemid 40052428)
25. Ikeda H, Lethé B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199-208.
26. Watari K, Tojo A, Nagamura-Inoue T, et al. Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene. FEBS Lett 2000;466:367-71.
27. Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 2005;102:6092-7.
28. Epping M, Wang L, Edel M, et al. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005;122:835-47.
29. Remmele W, Stegner H. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-40.
30. Landis R, Koch G. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
31. Kohlberger P, Breitenecker F, Kaider A, et al. Modified true-color computer-assisted image analysis versus subjective scoring of estrogen receptor expression in breast cancer: a comparison. Anticancer Res 1999;19:2189-93.
32. Remmele W, Schicketanz K. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 1993;189:862-6.
33. Yang J, Price MA, Neudauer CL, et al. Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol 2004;165:881-91.
34. Mould A, Askari J, Craig S, et al. Integrin alpha4beta1-mediated melanoma cell adhesion and migration on vascular cell adhesion molecule-1 (VCAM-1) and the alternatively spliced IIICS region of fibronectin. J Biol Chem 1994;269:27224-30.
35. Anastassiou G, Esser M, Bader E, et al. Expression of cell adhesion molecules and tumour infiltration leucocytes in conjunctival melanoma. Melanoma Res 2004;14:381-5.
36. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-93.
37. Freemantle S, Spinella M, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003;22:7305-15.
38. Steinbach D, Hermann J, Viehmann S, et al. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 2002;133:118-23. (Pubitemid 34279642)
39. Doolan P, Clynes M, Kennedy S, et al. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat 2008;109:359-65. (Pubitemid 351644842)